Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Type 1 diabetes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,047 result(s) found for: Type 1 diabetes. Displaying page 1 of 103.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-000007-17 Sponsor Protocol Number: TAK-875_309 Start Date*: 2013-06-05
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50mg Compared With Placebo as an Add-On to Glimepiride ...
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10027433 - Metabolism and nutrition disorders 10029505 Non-insulin-dependent diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001752-10 Sponsor Protocol Number: TAK-875_302 Start Date*: 2012-10-30
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When...
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10027433 - Metabolism and nutrition disorders 10029505 Non-insulin-dependent diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002741-35 Sponsor Protocol Number: TAK-875_301 Start Date*: 2012-02-15
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10029505 Non-insulin-dependent diabetes mellitus LLT
    14.0 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    14.0 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-001222-27 Sponsor Protocol Number: EU-IIT-006 Start Date*: 2007-11-06
    Sponsor Name:Imperial College London
    Full Title: The effect of Pioglitazone on vascular and ventricular function in people with type 2 diabetes PICCOLA
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    9.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011672-29 Sponsor Protocol Number: NN1250-3585 Start Date*: 2009-11-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial investigating the efficacy and safety of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen
    Medical condition: type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008296-33 Sponsor Protocol Number: 1218.36 Start Date*: 2009-06-29
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic pa...
    Medical condition: Type 2 diabetes pretreated with basal Insulin therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049746 Insulin-requiring type II diabetes mellitus LLT
    9.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    9.1 10029505 Non-insulin-dependent diabetes mellitus LLT
    9.1 10053247 Insulin-requiring type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) NL (Completed) ES (Completed) SK (Completed) BE (Completed) CZ (Completed) IT (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004528-11 Sponsor Protocol Number: BM18102 Start Date*: 2005-04-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    7 10012613 low
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-000019-27 Sponsor Protocol Number: 0431-049 Start Date*: 2007-03-14
    Sponsor Name:Merck & Co., Inc
    Full Title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
    Medical condition: type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) IE (Completed) HU (Completed) DK (Completed) ES (Completed) GB (Completed) AT (Completed) GR (Completed) DE (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-007805-58 Sponsor Protocol Number: KP-MSD-01-08 Start Date*: 2009-11-16
    Sponsor Name:Med. Klinik II, Grosshadern, Klinikum der Universität München
    Full Title: The effect of sitagliptin on postprandial lipoprotein metabolism in patients with diabetes mellitus type 2
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    9.1 10012619 Diabetes mellitus poor control LLT
    9.1 10045242 Type II diabetes mellitus LLT
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021057-39 Sponsor Protocol Number: NN2211-1800 Start Date*: 2010-11-11
    Sponsor Name:Novo Nordisk A/S
    Full Title: A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Paediatric (10 – 17 years old) Subjects with Type 2 Diabetes
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015255-25 Sponsor Protocol Number: 1218.63 Start Date*: 2010-03-03
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of linagliptin (5 mg), administered orally once daily over 24 weeks in type 2 diabetic patients (...
    Medical condition: Patients with type 2 diabetes.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012317-22 Sponsor Protocol Number: PBBT Start Date*: 2009-12-04
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: PEDIATRIC BASAL BOLUS THERAPY - Basal-Bolus regimen in the treatment of children with type 1 diabetes
    Medical condition: pre-puberal children with T1DM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023253 LLT
    9.1 10021211 LLT
    9.1 10045238 LLT
    9.1 10045228 LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001227-45 Sponsor Protocol Number: PHT/2017/20 Start Date*: 2017-06-12
    Sponsor Name:Portsmouth Hospitals NHS Trust
    Full Title: Comparison of ambulatory glucose profile prior to and during pancreatic enzyme replacement therapy in patients with diabetes and pancreatic exocrine insufficiency: a single-arm phase IV trial
    Medical condition: Type 1 diabetes and type 2 diabetes mellitus Pancreatic exocrine insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.1 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    20.0 100000004856 10033628 Pancreatic insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002160-22 Sponsor Protocol Number: 0431-028 Start Date*: 2004-11-17
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431 Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Co...
    Medical condition: Type 2 Diabetes Mellitus Chronic Renal Insufficiency [MedDRA classification code: 10050441]
    Disease: Version SOC Term Classification Code Term Level
    7.0 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004137-42 Sponsor Protocol Number: 0431-066 Start Date*: 2007-10-28
    Sponsor Name:Merck Sharp & Dohme GmbH
    Full Title: A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pat...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IE (Completed) HU (Completed) SE (Completed) SI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004965-22 Sponsor Protocol Number: NN9535-4339 Start Date*: 2017-06-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) HU (Completed) FR (Completed) FI (Completed) ES (Completed) SE (Completed) BG (Completed) GB (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004881-34 Sponsor Protocol Number: EFC5825 Start Date*: 2005-05-04
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve patients with type 2 ...
    Medical condition: Patients with Type 2 diabetes not treated by a pharmacological agent.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004833-40 Sponsor Protocol Number: EFC10518 Start Date*: 2008-05-14
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A randomized, double blind, placebo controlled study evaluating the glycemic effect of rimonabant added to metformin in patients with type 2 diabetes insufficiently controlled with metformin monoth...
    Medical condition: Type 2 Diabetes patients insufficiently controlled with metformin monotherapy
    Disease: Version SOC Term Classification Code Term Level
    10.1 10067585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-003808-35 Sponsor Protocol Number: CL2-44497-004 Start Date*: 2007-11-13
    Sponsor Name:Servier Research and Development Ltd.
    Full Title: Dose ranging study of S 44497 administered orally once daily for four weeks in type 2 diabetic patients. A multicentre, randomised, double-blind, double-dummy, phase II study versus placebo and gli...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012613 Diabetes mellitus non-insulin-dependent PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005375-91 Sponsor Protocol Number: NN9535-4216 Start Date*: Information not available in EudraCT
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) DE (Completed) GB (Completed) SK (Completed) LV (Completed) LT (Completed) GR (Completed) ES (Completed) PT (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:14:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA